Statera Biopharma, Inc. Common Stock
STAB
STAB was delisted on the 11th of January, 2023.
1 hedge funds and large institutions have $30 invested in Statera Biopharma, Inc. Common Stock in 2023 Q2 according to their latest regulatory filings, with funds opening new positions, increasing their positions, 0 reducing their positions, and 3 closing their positions.
75% less funds holding
Funds holding: 4 → 1 (-3)
100% less capital inflows, than outflows
Capital inflows: $0 | Capital outflows: $3.27K
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 3
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
-$3K |
| 2 |
IFP Advisors
Tampa,
Florida
|
-$271 |
STAB Hedge Fund Activity: Q2 2023 in Review
1 of the 6,389 institutional investors tracked by Wall St. Rank reported a position in Statera Biopharma, Inc. Common Stock (STAB) for Q2 2023, worth a combined $30 — down 99% from $3.29K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of STAB and 0 opened new positions — a net loss of 3 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Acadian Asset Management, exiting entirely with an estimated $3K sold.
- 1 institutional investor held Statera Biopharma, Inc. Common Stock (STAB) as of Q2 2023, down from 4 in Q1 2023.
- Funds reported $30 of Statera Biopharma, Inc. Common Stock stock for Q2 2023, down 99% quarter-over-quarter.
- 0 funds opened new Statera Biopharma, Inc. Common Stock positions in Q2 2023 and 3 closed out, a net change of -3 holders.
- The largest Statera Biopharma, Inc. Common Stock seller in Q2 2023 was Acadian Asset Management, an estimated $3K sold.
Based on aggregated 13F filings for Q2 2023.